The Department of Pharmaceuticals (DoP) is targeting the production of pharmaceuticals under the production linked incentive (PLI) scheme for pharmaceuticals at Rs. 90,000 crore during the fiscal year 2024-25. The investment committed for the scheme during fiscal year is around Rs. 5,000 crore.
Cupid Limited, a leading name in the contraceptive and personal wellness industry, proudly announces its enhanced e-commerce presence on India's premier online marketplaces, including Amazon.in, Flipkart, and 1mg.
Glenmark Life Sciences Ltd has reported Standalone financial results for the period ended June 30, 2024.nnGlenmark Life Sciences has posted net profit of Rs. 111.483 crores for the period ended June 30, 2024 as against net profit of Rs. 97.937 crores for the period ended March 31, 2024. The company posted net profit of Rs.135.450 crores for the period ended June 30, 2023.
Emcure Pharmaceuticals Ltd., one of the leading Indian pharmaceutical company with a differentiated product portfolio, together with its subsidiary Gennova Biopharmaceuticals Limited announces the signing of a 22.78 MWp DC Solar Power Purchase Agreement (PPA) with Sunsure Energy, one of India's leading renewable power producers.
Sun Pharmaceutical Industries Ltd announced that the USFDA has approved its drug LEQSELVI (deuruxolitinib) for treating adults with severe alopecia areata. The approval is based on Phase 3 clinical trials involving 1,220 patients. LEQSELVI provides a new treatment option for patients with significant hair loss due to this autoimmune disorder.nnRead more at:nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharmas-drug-to-treat-alopecia-areata-gets-usfda-nod/articleshow/112032939.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Notice of closure of trading window
Rusan Pharma’s API Plant in Ankleshwar (India) Receives USFDA GMP Approval
Syngene International Limited announced its first quarter results. Reported revenue from operations declined 2% year-on-year to Rs. 790 crores. Reported profit after tax declined 19% year-on-year to Rs 76 crores.
Torrent Pharmaceuticals Limited has reported consolidated financial results for the period ended June 30, 2024.
Thyrocare Technologies has posted net profit of Rs. 24.17 crores for the period ended June 30, 2024 as against net profit of Rs. 17.78 crores for the period ended March 31, 2024. The company has posted net profit of Rs.17.30 crores for the period ended June 30, 2023.